News
CANF
3.400
-1.16%
-0.040
Can-Fite Announces Peer-Reviewed Publication Of Piclidenoson Data In Canine Osteoarthritis Study
NASDAQ · 6d ago
Can-Fite and Vetbiolix Gain Peer-Reviewed Validation for Piclidenoson in Canine Osteoarthritis
TipRanks · 6d ago
Can-Fite BioPharma Announces Publication Of Peer-Reviewed Scientific Article On Findings From Study Evaluating Piclidenoson For Treatment Of Canine Osteoarthritis
Benzinga · 6d ago
Can-Fite says Piclidenoson study shows mobility, pain improvements in canine osteoarthritis
PUBT · 6d ago
Weekly Report: what happened at CANF last week (0511-0515)?
Weekly Report · 6d ago
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Barchart · 6d ago
Can-Fite Biopharma Raised to Buy From Hold by D. Boral Capital
Dow Jones · 05/13 21:24
Can-Fite Biopharma Price Target Announced at $7.00/Share by D. Boral Capital
Dow Jones · 05/13 21:24
D. Boral Capital Upgrades Can Fite Biopharma to Buy, Announces $7 Price Target
Benzinga · 05/13 21:14
Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital
TipRanks · 05/13 13:49
Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data
TipRanks · 05/13 11:28
Can-Fite BioPharma Plans To Advance Pancreatic Cancer Program Into Phase 2b Study Evaluating Namodenoson In Combination With Immunotherapy In Patients With Advanced Pancreatic Cancer
Benzinga · 05/13 11:06
BRIEF-Following Positive Phase 2A Pancreatic Cancer Data, Can-Fite Advances Namodenoson Into Phase 2B Combination Study With Immunotherapy
Reuters · 05/13 11:01
Can-Fite advances Namodenoson into Phase 2b pancreatic cancer immunotherapy combination trial
PUBT · 05/13 11:01
CAN FITE BIOPHARMA LTD - TO ADVANCE NAMODENOSON INTO PHASE 2B PANCREATIC CANCER STUDY WITH IMMUNOTHERAPY
Reuters · 05/13 11:00
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
TipRanks · 05/12 10:49
Can-Fite Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/12 10:46
Can-Fite Biopharma Price Target Raised to $5.00/Share From $2.50 by HC Wainwright & Co.
Dow Jones · 05/12 10:46
HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5
Benzinga · 05/12 10:36
Weekly Report: what happened at CANF last week (0504-0508)?
Weekly Report · 05/11 09:41
More
Webull provides a variety of real-time CANF stock news. You can receive the latest news about Can-Fite BioPharma Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.